年轻宫颈鳞癌组织中c-Myc和COX-2相关性及与血管生成的关系  

The expression and significance of c-Myc and COX-2 in cervix neoplasms of young women

作　　者：王雅楠[1] 李丽[2] 吴士茜[2] 孙冬霞[1] 孔卫平[1] 魏兰[1] 

机构地区：[1]邯郸市妇幼保健院,河北邯郸056001 [2]邯郸市中心医院,河北邯郸056001

出　　处：《现代肿瘤医学》2014年第3期625-628,共4页Journal of Modern Oncology

摘　　要：目的:研究原癌基因(c-Myc)和环氧合酶-2(COX-2)在35岁以下宫颈上皮内瘤样病变(CIN)和宫颈鳞癌(SCC)患者中的表达及与微血管密度(MVD)的相关性,探讨c-Myc和COX-2在SCC发生发展中的关系及与临床病理关系。方法:选择我院手术切除的SCC组织标本40例、CIN标本31例、正常宫颈组织(NCE)10例,采用免疫组化SP法检测各组c-Myc和COX-2的表达情况及微血管密度(MVD)(CD34标记)。并通过统计学方法分析其表达情况及与肿瘤分期、病理分型、淋巴结转移等之间的相互关系。结果:c-Myc在年轻SCC中的阳性表达率为62.5%(25/40),显著高于CIN组和NCE组(P<0.01),c-Myc在年轻SCC中的表达与分化及淋巴结转移有关(P<0.01),但与分期无关。年轻SCC组中COX-2阳性表达率为67.5%(27/40),显著高于CIN组和NCE组(P<0.01),COX-2的表达与SCC的分期及淋巴结转移有相关性(P<0.01)。相关性分析发现两者在SCC组织中表达呈正相关,两者在宫颈癌血管生成中可能具有协同作用。结论:c-Myc和COX-2在年轻SCC发生、发展中起重要作用,c-Myc和COX-2上调表达可作为SCC预后的判断指标。Objectlve：To determine the expression of COX -2 and c - Myc in cervix neoplasms,CiN and SCC a- mong young women under 35 and the research of MVD,to discuss the relationship between COX - 2 and c - Myc in SCC. Methods：To detect the expressions of COX -2,c - Myc and micro vessel density（MVD） labeled by CIN3 in 40 cases in SCC,31 cases of CIN and 10 cases of NCE by immunohistochemistt7 S - P. And analyze the relationship with histological grade, pathological type,axillary lymph node metastasis. Results：The positive expression rate of c - Myc in SCC was 62.5% （25/40） which was significantly higher than that in CIN and NCE（P 〈0.01） ,the expression of c - Myc was located with myometrial invasion and lymph node metastasis, but it was unrelated with the stage （P 〈 0.01）. The expression rate of COX - 2 in SCC was 67.5% （27/40） ,which was significantly higher than that in CIN and NCE （P 〈 0.01 ） ,the expression of COX - 2 was located with the stage of SCC and lymph node metastasis （P 〈 0.01 ）. Expressions of them were positively correlated in SCC. Conclusion： COX - 2 and c - Myc in SCC play an important role in SCC,the high expressions of COX- 2 and c- Myc were meaningful.

关 键 词：子宫内膜肿瘤 C-MYC蛋白 COX-2蛋白 免疫组织化学 

分 类 号：R737.33[医药卫生—肿瘤]